Last reviewed · How we verify
Pramlintide and Metreleptin
At a glance
| Generic name | Pramlintide and Metreleptin |
|---|---|
| Also known as | Symlin |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide (NA)
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects (PHASE2)
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin (PHASE2)
- Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects (PHASE2)
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pramlintide and Metreleptin CI brief — competitive landscape report
- Pramlintide and Metreleptin updates RSS · CI watch RSS
- AstraZeneca portfolio CI